Global barriers to decision makers for prioritizing interventions for obesity

The treatment of obesity remains underprioritized. New pharmacologic options for the treatment of obesity have shown effectiveness and safety but are not widely reimbursed. Despite the unmet need and the existence of effective prevention and treatment strategies, substantial barriers exist to effectively address obesity as a disease. The purpose of this scoping review was to investigate the barriers for decision makers in prioritizing interventions for obesity and to seek out interconnection between barriers to prevention and treatment. A scoping review was conducted using a systematic search of both scientific databases and Health Technology Assessment (HTA) databases. Studies that addressed barriers to reimbursement or prioritization of obesity treatment and prevention were included. A total of 26 articles and 14 HTAs were included. Four main barriers for decision makers to prioritize new interventions for obesity were identified: perceptions, knowledge, economics, and politics. There was a high degree of interconnectedness among barriers, as well as large overlaps between barriers in relation to bariatric surgery, pharmacologic treatments, and prevention regulation. Multiple barriers exist that impact decision makers in prioritizing interventions for treating obesity. A strong interconnectedness of the barriers was found, indicating a systems approach to improve global prioritization to address the disease. This study suggests that decision makers should carefully consider all main barriers when addressing the obesity epidemic.

Authors

Institutions

Publication Details

Journal
International Journal of Obesity
Published
2024-10-16
DOI
https://doi.org/10.1038/s41366-024-01650-z
Citations
4
Primary Topic
Obesity and Health Practices
Type
article
Field-Weighted Citation Impact
3.77

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Global barriers to decision makers for prioritizing interventions for obesity

Carel Wynand le Roux, Jens‐Christian Holm, Rasmus H. Olesen, Lars Holger Ehlers et al.
4 citations
International Journal of Obesity
Obesity and Health Practices
3.77
article

Global barriers to decision makers for prioritizing interventions for obesity

Carel Wynand le Roux, Jens‐Christian Holm, Rasmus H. Olesen, Lars Holger Ehlers, Phil C. McEwan, Nicoline Weinreich Reinstrup
article en
4 citations

Abstract

The treatment of obesity remains underprioritized. New pharmacologic options for the treatment of obesity have shown effectiveness and safety but are not widely reimbursed. Despite the unmet need and the existence of effective prevention and treatment strategies, substantial barriers exist to effectively address obesity as a disease. The purpose of this scoping review was to investigate the barriers for decision makers in prioritizing interventions for obesity and to seek out interconnection between barriers to prevention and treatment. A scoping review was conducted using a systematic search of both scientific databases and Health Technology Assessment (HTA) databases. Studies that addressed barriers to reimbursement or prioritization of obesity treatment and prevention were included. A total of 26 articles and 14 HTAs were included. Four main barriers for decision makers to prioritize new interventions for obesity were identified: perceptions, knowledge, economics, and politics. There was a high degree of interconnectedness among barriers, as well as large overlaps between barriers in relation to bariatric surgery, pharmacologic treatments, and prevention regulation. Multiple barriers exist that impact decision makers in prioritizing interventions for treating obesity. A strong interconnectedness of the barriers was found, indicating a systems approach to improve global prioritization to address the disease. This study suggests that decision makers should carefully consider all main barriers when addressing the obesity epidemic.

International Journal of ObesityVol. 49(2)
University College Dublin (IE), Institute of Health Economics (CA), Health Economics and Outcomes Research (United Kingdom) (GB), Holbæk Sygehus (DK)
Eli Lilly and Company, Pfizer, AstraZeneca, Gilead Sciences, Novocure, Science Foundation Ireland, Irish Research Council, Novo Nordisk
Good health and well-being
Openalex Percentile: Top 7%
Obesity and Health Practices
3.77
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.